(TLSA) Tiziana Life Sciences - Ratings and Ratios
Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: BMG889121031
TLSA: Monoclonal Antibody, Small Molecule Inhibitor
Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a biotechnology company specializing in the discovery and development of innovative therapeutics for oncology and immunology. The companys pipeline includes a diverse range of candidates targeting various inflammatory and autoimmune diseases. Its lead product candidate, Foralumab (TZLS-401), is a first-in-class, fully human anti-CD3 monoclonal antibody designed to modulate T-cell responses. This candidate is being investigated for multiple indications, including Crohns disease, ulcerative colitis, graft-versus-host disease, multiple sclerosis, type-1 diabetes, psoriasis, and rheumatoid arthritis. Foralumabs unique mechanism of action, which involves partial agonism of the CD3 receptor, aims to restore immune homeostasis while minimizing the risk of severe immune activation associated with full agonist anti-CD3 antibodies.
The company also develops Milciclib (TZLS-201), a small molecule inhibitor with broad-spectrum activity against cyclin-dependent kinases (CDKs) and Src family kinases. This candidate has shown promise in treating solid tumors, including hepatocellular carcinoma (HCC), and is being explored in combination with other therapies to enhance efficacy. Additionally, Tiziana is advancing TZLS-501, a fully human monoclonal antibody targeting the interleukin-6 (IL-6) receptor, which plays a key role in chronic inflammation and oncology. IL-6 signaling is implicated in various diseases, including rheumatoid arthritis, inflammatory bowel disease, and certain cancers, making TZLS-501 a versatile candidate with potential across multiple indications.
Founded in 1998 and headquartered in London, United Kingdom, Tiziana Life Sciences has established itself as a pioneer in the development of novel immunomodulatory therapies. The companys focus on addressing unmet medical needs in autoimmune diseases and oncology positions it as a key player in the biotechnology sector. Tizianas strategic approach includes leveraging its expertise in monoclonal antibodies and small molecule inhibitors to deliver targeted therapies with improved safety and efficacy profiles.
Objective: Tiziana Life Sciences Ltd aims to revolutionize the treatment of autoimmune and inflammatory diseases by developing cutting-edge therapeutics that target the underlying mechanisms of immune dysregulation. The company is committed to advancing its pipeline through rigorous clinical testing and strategic collaborations to bring innovative treatments to patients in need. 3-Month Forecast: Based on the providedAdditional Sources for TLSA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TLSA Stock Overview
Market Cap in USD | 175m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2000-03-24 |
TLSA Stock Ratings
Growth 5y | 6.84% |
Fundamental | -38.7% |
Dividend | 0.0% |
Rel. Strength Industry | 235 |
Analysts | - |
Fair Price Momentum | 1.59 USD |
Fair Price DCF | - |
TLSA Dividends
No Dividends PaidTLSA Growth Ratios
Growth Correlation 3m | 42.6% |
Growth Correlation 12m | 35.5% |
Growth Correlation 5y | -64.9% |
CAGR 5y | 11.95% |
CAGR/Max DD 5y | 0.13 |
Sharpe Ratio 12m | -0.04 |
Alpha | 215.76 |
Beta | -1.64 |
Volatility | 137.72% |
Current Volume | 377.2k |
Average Volume 20d | 886.5k |
As of March 16, 2025, the stock is trading at USD 1.57 with a total of 377,219 shares traded.
Over the past week, the price has changed by -7.10%, over one month by +98.23%, over three months by +68.93% and over the past year by +209.30%.
Probably not. Based on ValueRay Fundamental Analyses, Tiziana Life Sciences (NASDAQ:TLSA) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -38.66 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TLSA as of March 2025 is 1.59. This means that TLSA is currently overvalued and has a potential downside of 1.27%.
Tiziana Life Sciences has no consensus analysts rating.
According to ValueRays Forecast Model, TLSA Tiziana Life Sciences will be worth about 1.7 in March 2026. The stock is currently trading at 1.57. This means that the stock has a potential upside of +8.92%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3 | 91.1% |
Analysts Target Price | 3 | 91.1% |
ValueRay Target Price | 1.7 | 8.9% |